Raleigh, NC-based drug developer BioDelivery Sciences International ($BDSI) has inked a licensing deal for its painkiller Onsolis to Collegium Pharmaceutical ($COLL). Under terms of the deal, BioDelivery could see up to $23.5 million plus sales royalties.
Under the agreement, BioDelivery grants exclusive U.S. rights to Collegium to develop and commercialize Onsolis (fentanyl buccal soluble film).
Onsolis uses BioDelivery’s BioErodible MucoAdhesive drug delivery technology, which is a small, bioerodible polymer film that is placed on the inner lining of the cheek. It’s an opioid analgesic indicated only for the management of breakthrough pain in patients with cancer.
Two weeks ago, the FDA approved Collegium’s Xtampza ER, a version of the painkiller oxycodone that features properties that will deter the drug’s abuse. Xtampza uses microsphere-in-capsule technology that is designed to provide pain control while maintaining its drug profile even if it’s crushed or chewed, a common form of drug abuse manipulation.
“We are very pleased to enter into this important partnership with a company that has a focus in the pain management area,” Mark Sirgo, president and CEO of BioDelivery, said in a statement. “We believe there remains a significant need for novel delivery technologies for the treatment of breakthrough cancer pain, and we look forward to Onsolis potentially returning to the market by mid-2017.”
Under the financial terms of the deal, BioDelivery gets $2.5 million upfront, reimbursement for remaining expenses associated with the transfer, $4 million for the first commercial sale of Onsolis in the U.S., and up to $17 million depending on performance and sales milestones. Additionally, BioDelivery will get an “upper-teens” percentage of royalties based on U.S. net sales.
- check out the release
Image courtesy of James Willamor CC BY-SA 2.0